Clinical Trial Update: Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10% [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating nivolumab after cyclophosphamide and doxorubicin induction in NSCLC with PD-L1 <10%. Status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• nivolumab (nivolumab)

Snippet

Sponsor: National Cancer Center, Korea | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN